The Impact of Sage Extract on GTS B and D Gene Expression in S. Mutans
The Impact of Natural Sage Extract on Glucosyltransferase B and D Gene Expression in Streptococcus Mutans: A Randomized Clinical Trial Using Real Time Polymerase Chain Reaction
Glucosyltransferases (Gtfs) play a crucial role in the pathogenesis of dental caries caused by Streptococcus mutans. Gtfs is recognized as an attractive target for effective therapeutic interventions aimed at inhibiting cariogenic biofilms.
Objective: This study evaluates the antibacterial effects of sage extract compared to chlorhexidine mouthwashes on the expression of Gtf genes in S. mutans from salivary samples of high caries risk patients over a one-month follow-up, utilizing real-time polymerase chain reaction.
Methodology: This clinical trial involves 42 participants with a high risk for caries, who are randomly divided into two groups of 21 subjects each.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Glucosyltransferases (Gtfs) are essential in the development of dental caries caused by Streptococcus mutans. They are currently recognized as promising targets for effective therapeutic strategies aimed at disrupting cariogenic biofilms.
Objective: This study investigates the antibacterial effects of sage extract in comparison to chlorhexidine mouthwashes on the expression of Gtf genes in S. mutans from the saliva of patients at high risk for caries, over a one-month follow-up period, using real-time polymerase chain reaction.
Methodology: This clinical trial includes 42 high caries risk participants, who are randomly assigned to two groups, each consisting of 21 subjects.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Cairo University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- medically free, high caries patient with DMFT
Exclusion Criteria:
- pregnant and smokers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sage oil mouthwash
Sage oil obtained from a local market of herbal products in Egypt.
In order to identify chemical composition of sage essential oils and overall purity, Gas Chromatography/ Mass Spectrometry analysis (GC/MS) performed
|
Sage oil obtained from a local market of herbal products in Egypt.
In order to identify chemical composition of sage essential oils and overall purity, Gas Chromatography/ Mass Spectrometry analysis (GC/MS) performed
Other Names:
|
|
Active Comparator: Chlorohexidine Mouthwash
0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, and sodium saccharin
|
0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, and sodium saccharin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
real-time PCR
Time Frame: 1 week
|
S. Mutans, Gtf B, Gtf D
|
1 week
|
|
real-time PCR
Time Frame: 2 weeks
|
S. Mutans, Gtf B, Gtf D
|
2 weeks
|
|
real-time PCR
Time Frame: 3 weeks
|
S. Mutans, Gtf B, Gtf D
|
3 weeks
|
|
real-time PCR
Time Frame: 4 weeks
|
S. Mutans, Gtf B, Gtf D
|
4 weeks
|
|
Gene Expression
Time Frame: 1 week
|
S. Mutans, Gene Expression
|
1 week
|
|
Gene Expression
Time Frame: 2 weeks
|
S. Mutans, Gene Expression
|
2 weeks
|
|
Gene Expression
Time Frame: 3 weeks
|
S. Mutans, Gene Expression
|
3 weeks
|
|
Gene Expression
Time Frame: 4 weeks
|
S. Mutans, Gene Expression
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Sage Extract
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dental Caries
-
NCT04945382Not yet recruitingPit and Fissure Caries | Caries,Dental | Sealant Dental
-
NCT04365270CompletedPulpitis | Caries | Caries,Dental | Reversible Pulpitis | Caries Class I | Caries; Dentin
-
NCT04286256Completed
-
NCT06882343Not yet recruitingDeep Caries | Caries, Dental
-
NCT03969628Recruiting
-
NCT05231330Completed
-
NCT04147091Completed
-
NCT04790383RecruitingCaries,Dental | Caries Class II
Clinical Trials on Chlorohexidine Mouthwash
-
NCT04565912Unknown
-
NCT04566120CompletedHigh Caries Risk Patients | Streptococcus Mutans
-
NCT03590977Unknown
-
NCT06792812CompletedMouth Diseases | Stress | Bleeding Gum
-
NCT05951647Not yet recruiting
-
NCT07490873RecruitingEffectiveness of Chlorohexidine | Effectiveness of Essential Oil | Effectiveness of Cetylpyridinium Chloride
-
NCT02008500CompletedDentinal Hypersensitivity
-
NCT07364565RecruitingGingivitis | Dental Plaque | Gingival Inflammation | Gingival Bleeding | Patient Reported Outcome | Gingival Inflammation and Bleeding
-
NCT07172009RecruitingGlucose Metabolism Disorders (Including Diabetes Mellitus)
-
NCT02385708CompletedSurgical Site Infection